Simultaneous National Scientific Advice for Timely Multi-Regulatory Authority Feedback
Scientific advice is a regulatory process expected to, “facilitate timely access to safe and efficacious medicinal products to patients and users of medicines by optimizing research and development, reducing uncertainties about regulatory outcomes, and accelerating time to approval of a marketing authorization application”. Applicants commonly seek advice centrally from the European Medicine’s Agency (EMA) or nationally from individual Member State (MS) Regulatory Authorities (RAs). Beginning in February 2020, the EU-Innovation Network (EU-IN) of the Head of Medicines Agencies (HMA) initiated a pilot program for Simultaneous National Scientific Advice (SNSA) as an additional opportunity for RA engagement. This white paper addresses why it is important for developers to understand the SNSA process and when it should be considered as part of a broader drug development strategy.
Legal and Regulatory Considerations to Implement Decentralized Clinical Trials
With Decentralized Clinical Trials (DCTs) becoming more prevalent, so have the initiatives, recommendations, and regulations. Read about what to…
Navigating Global Regulatory CMC Processes During Public Health Crises
Chemistry, manufacturing, and controls (CMC) regulations are a critical part of the drug development path and the ongoing production and distribution…